Tetraphase Pharmaceuticals to Present XERAVA™ (Eravacycline) and TP-6076 Data at IDWeek 2018
September 19, 2018 06:00 ET
|
Tetraphase Pharmaceuticals, Inc.
– Four Abstracts Selected for Poster Presentations – – TP-6076 Featured in Oral Presentation – WATERTOWN, Mass., Sept. 19, 2018 (GLOBE NEWSWIRE) -- Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH),...
Tetraphase Pharmaceuticals Announces FDA Approval of XERAVA™ (Eravacycline) for Complicated Intra-Abdominal Infections (cIAI)
August 27, 2018 16:19 ET
|
Tetraphase Pharmaceuticals, Inc.
– XERAVA™ Achieved High Clinical Cure Rates in Clinical Trials in Patients with cIAI – – Broad Product Label for Treatment of cIAI – – Commercial Launch Expected in the Fourth Quarter of 2018 – –...
CORRECTING and REPLACING -- Tetraphase Pharmaceuticals to Participate at Upcoming Investor Conference
August 27, 2018 12:00 ET
|
Tetraphase Pharmaceuticals, Inc.
WATERTOWN, Mass., Aug. 27, 2018 (GLOBE NEWSWIRE) -- In a release issued earlier today by Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH) please note that the upcoming investor conference details have...
Tetraphase Pharmaceuticals to Participate at Upcoming Investor Conferences
August 27, 2018 06:00 ET
|
Tetraphase Pharmaceuticals, Inc.
WATERTOWN, Mass., Aug. 27, 2018 (GLOBE NEWSWIRE) -- Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH), a biopharmaceutical company focused on developing and commercializing novel antibiotics to treat...
Tetraphase Pharmaceuticals Reports Second Quarter 2018 Financial Results and Recent Highlights
August 02, 2018 16:10 ET
|
Tetraphase Pharmaceuticals, Inc.
WATERTOWN, Mass., Aug. 02, 2018 (GLOBE NEWSWIRE) -- Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH), a biopharmaceutical company focused on developing and commercializing novel antibiotics to treat...
Tetraphase Pharmaceuticals Receives Positive CHMP Opinion for Xerava™ (eravacycline) as a Treatment for Complicated Intra-Abdominal Infections
July 27, 2018 08:30 ET
|
Tetraphase Pharmaceuticals, Inc.
WATERTOWN, Mass., July 27, 2018 (GLOBE NEWSWIRE) -- Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH), a biopharmaceutical company focused on developing and commercializing novel antibiotics to treat...
Tetraphase Pharmaceuticals Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
July 12, 2018 16:01 ET
|
Tetraphase Pharmaceuticals, Inc.
WATERTOWN, Mass., July 12, 2018 (GLOBE NEWSWIRE) -- Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH), a biopharmaceutical company focused on developing and commercializing novel antibiotics to treat...
Tetraphase Pharmaceuticals Announces Data from a Pooled Analysis of IGNITE1 and IGNITE4 Phase 3 Trials Evaluating Eravacycline in Complicated Intra-Abdominal Infections at the ASM Microbe 2018 Annual Meeting
June 11, 2018 06:30 ET
|
Tetraphase Pharmaceuticals, Inc.
WATERTOWN, Mass., June 11, 2018 (GLOBE NEWSWIRE) -- Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH), a biopharmaceutical company focused on developing and commercializing novel antibiotics to treat...
Tetraphase Pharmaceuticals Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
June 08, 2018 16:01 ET
|
Tetraphase Pharmaceuticals, Inc.
WATERTOWN, Mass., June 08, 2018 (GLOBE NEWSWIRE) -- Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH), a biopharmaceutical company focused on developing and commercializing novel antibiotics to treat...
Tetraphase Pharmaceuticals Announces Everest Medicines’ Submission of an Investigational New Drug Application for Eravacycline in Complicated Intra-Abdominal Infection to the China Food and Drug Administration
June 04, 2018 06:00 ET
|
Tetraphase Pharmaceuticals, Inc.
WATERTOWN, Mass., June 04, 2018 (GLOBE NEWSWIRE) -- Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH), a biopharmaceutical company focused on developing and commercializing novel antibiotics to treat...